BioPharma Resources

Drug Trial Radar · NCT04880031

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Sep 30, 2021

Primary completion

Oct 27, 2025

Study completion Oct 27, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

  • EfimosferminDrug

    Efimosfermin will be administered by subcutaneous injection

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A, Part B, Part C, and Part D: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: Until End of study/Early Termination (Day 393)
  2. Part A, Part B, Part C, and Part D: Changes from Baseline in systolic and diastolic blood pressure (BP)Time frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)
  3. Part A, Part B, Part C, and Part D: Changes from Baseline in heart rateTime frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)
  4. Part A, Part B, Part C, and Part D: Number of participants with Grade 3 and Grade 4 laboratory abnormalitiesTime frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Central Research Associates

    Birmingham, Alabama

  • Arizona Liver Health

    Chandler, Arizona

  • Arizona Liver Health

    Peoria, Arizona

  • Arizona Liver Health

    Tucson, Arizona

  • Liver Institute PPLC

    Tucson, Arizona

  • QLMC

    Tucson, Arizona

  • Alliance Research Institute

    Canoga Park, California

  • Ark Clinical Research

    Fountain Valley, California

  • Fresno Clinical Research Center

    Fresno, California

  • Catalina Research Institute

    Montclair, California

  • Knowledge Research Center

    Orange, California

  • FOMAT Medical Research

    Oxnard, California

  • Inland Empire Clinical Trials

    Rialto, California

  • Southwest General Healthcare Center

    Fort Myers, Florida

  • Covenant Metabolic Specialists - Fort Myers

    Fort Myers, Florida

  • Evolution Clinical Trials

    Hialeah Gardens, Florida

  • Entrust Clinical Research Center

    Kendall, Florida

  • Galenus Group

    Lehigh Acres, Florida

  • G+C Research Group

    Miami, Florida

  • Miami Clinical Research

    Miami, Florida

  • Advanced Clinical Research

    Miami, Florida

  • Admed Research

    Miami, Florida

  • Century Research

    Miami, Florida

  • Panex Clinical Research

    Miami Lakes, Florida

  • Charter Research

    Orlando, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Covenant Metabolic Specialists - Sarasota

    Sarasota, Florida

  • Tandem Clinical Research

    Marrero, Louisiana

  • Kansas City Research Institute

    Kansas City, Missouri

  • Coastal Research Institute, LLC

    Fayetteville, North Carolina

  • Lillestol Research LLC

    Fargo, North Dakota

  • Velocity Clinical Research

    East Greenwich, Rhode Island

  • Accelemed Research

    Austin, Texas

  • Pinnacle Clinical Research - Austin

    Austin, Texas

  • Texas Liver Institute - Austin

    Austin, Texas

  • Apex Mobile Clinical Research

    Bellaire, Texas

  • South Texas Research Institute-Brownsville

    Brownsville, Texas

  • South Texas Research Institute-Edinburg

    Edinburg, Texas

  • Pinnacle Clinical Research - Georgetown

    Georgetown, Texas

  • Houston Research Institute

    Houston, Texas

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.